The UN's Double Standard: The US Government Patented Cannabis Medicine While Funding Global Prohibition
The architecture of global drug prohibition rests upon a single foundational legal premise: cannabis possesses no accepted medical value. This is the justification the United Nations used to enforce the 1961 Single Convention. It is the justification the US Drug Enforcement Administration uses to maintain Schedule I classification. It is the justification the Mauritian state uses to imprison citizens under the Dangerous Drugs Act 2000. On 7 October 2003, the United States Patent and Trademark Office formally granted Patent 6,630,507. The assignee was the United States of America as represented by the Department of Health and Human Services. The subject matter was the medical properties of cannabinoids. The same government that declared cannabis had no medical value owns the patent on its medical value.
There are contradictions in the historical record of cannabis prohibition, and then there is US Patent 6,630,507. The contradictions documented in previous articles of this edition, Harry Anslinger fabricating congressional testimony, the La Guardia Commission being buried, the WHO recommendation being resisted by a two-vote margin, are each instances of institutional dishonesty. Patent 6,630,507 is something categorically different. It is not a contradiction that requires historical reconstruction or archival research to establish. It is a public legal document, searchable at patents.google.com, filed and granted by the United States Patent and Trademark Office, in which the United States government formally asserted, under the full legal authority of intellectual property law, that cannabinoids have significant and specific medical value. The same government. The same substance. The same period during which global prohibition was being actively maintained and enforced. The document is public. The contradiction is absolute.
"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia."
Julius Axelrod Nobel Laureate cannabis patent NIH cannabinoids neuroprotection antioxidants blood-brain barrier stroke Alzheimer Parkinson
The research underpinning Patent 6,630,507 was conducted at the National Institutes of Health, the primary biomedical research agency of the United States federal government, by a team that included Dr Julius Axelrod, a Nobel Laureate in Physiology or Medicine. Axelrod received his Nobel Prize in 1970 for his work on neurotransmitters. His subsequent research into cannabinoid neuroprotection represents, in institutional terms, the United States government's most prestigious scientific minds formally confirming that cannabis compounds protect the brain rather than damage it.
The patent establishes that non-psychoactive cannabinoids, specifically CBD and related compounds, function as powerful antioxidants capable of crossing the blood-brain barrier. In practical terms, this means cannabinoids can enter brain tissue directly and protect neurons from oxidative damage, the mechanism through which stroke, traumatic brain injury, and neurodegenerative diseases destroy brain cells. The patent covers the use of cannabinoids for stroke recovery, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and HIV dementia. These are among the most significant and most prevalent neurological conditions in the world. The US government's own scientists, working at the government's own research institutions, producing research funded by the government's own budget, formally established that cannabis compounds are effective treatments for them. Then the same government maintained that cannabis had no medical value.
US government cannabis contradiction Schedule I no medical value HHS patent neuroprotectant DEA prohibition same government same period
| What the Left Hand Said | What the Right Hand Did |
|---|---|
| DEA Schedule I classification: cannabis has "no currently accepted medical use." Maintained continuously since 1970. | Patent 6,630,507: cannabinoids have "particular application as neuroprotectants" for stroke, Alzheimer's, Parkinson's, HIV dementia. Granted 2003. |
| US State Department, via the INCB: threatened Uruguay, pressured Canada, condemned the Netherlands for cannabis reform. Framed as protecting public health. | National Institutes of Health, with Nobel Laureate Julius Axelrod: formally documented cannabinoids as superior antioxidants that protect public health by preventing neurological damage. |
| US-funded global eradication programmes: billions spent burning cannabis crops in Colombia, Jamaica, Mexico, and across the Global South. Justified as eliminating a substance with no legitimate use. | US Patent Office: exclusive intellectual property rights held by the US Department of Health and Human Services for the medical applications of the same substance being burned in those same fields. |
| UN Single Convention 1961, Schedule IV: cannabis classified alongside heroin. No medical value. Exceptional public health risk. All signatory nations obligated to prohibit. | US Government patent portfolio: cannabinoid medical applications owned by the American state. The property whose existence the treaty denies is simultaneously the property whose value the patent affirms. |
For two decades, the right hand of the US government held a patent confirming that cannabis is a life-saving neuroprotectant. The left hand funded global task forces to burn cannabis fields in the Global South, justified by the claim that the plant had no legitimate use.
cannabis pharmaceutical monopoly patent strategy botanical plant criminalisation synthetic derivative profit model pharmaceutical industry
The existence of Patent 6,630,507 is not an accident of bureaucratic inefficiency. It reflects a coherent commercial strategy whose logic is straightforward and whose consequences are global. A naturally occurring botanical plant cannot be patented. Anyone on earth can grow Cannabis sativa L. in their garden for the cost of seeds, soil, and water. The raw plant, if legal, would cost approximately the same as mint or basil. No pharmaceutical company can own it. No government can extract rent from it in perpetuity.
However, if a government or a pharmaceutical conglomerate isolates specific cannabinoid molecules from the plant, characterises their pharmacological properties, and files a patent on their medical applications, a different economic reality emerges. The synthetic or highly purified derivative of a naturally occurring compound can be patented. The natural compound from which it is derived can simultaneously remain illegal. The citizen who cannot legally grow the plant in their garden can legally purchase the patented pharmaceutical version of its extracted compounds at the price the patent holder sets. The botanical source of medicine is criminalised. The pharmaceutical extraction of that same medicine is protected by intellectual property law and sold at a premium. The patent is the mechanism through which the pharmaceutical economy converts a freely available plant into a proprietary revenue stream.
Patent 6,630,507 is not merely evidence of government hypocrisy. It is the legal infrastructure of the pharmaceutical extraction model applied to cannabis. The Dangerous Drugs Act 2000 in Mauritius, which criminalises the botanical plant, is the enforcement mechanism that drives potential consumers toward the pharmaceutical derivatives. The two legal instruments, the criminal prohibition and the pharmaceutical patent, work together as a system. One closes the free market. The other opens the proprietary market. The citizen who suffers from Parkinson's disease or recovers from a stroke pays the price the system determines.
Mauritius cannabis US patent 6630507 Parkinson stroke Dangerous Drugs Act 2000 US treaty obligation medical value acknowledged
The Dangerous Drugs Act 2000 in Mauritius is enforced on the basis of the international prohibition framework established by the 1961 UN Single Convention, which classified cannabis in Schedule IV on the grounds that it possessed no medical value. The United States was the primary architect and enforcer of that classification.
Patent 6,630,507 establishes, as a matter of US federal intellectual property law granted in 2003, that the US Department of Health and Human Services believed cannabinoids had significant medical value for stroke, Alzheimer's disease, Parkinson's disease, and HIV dementia. The patent predates the 2020 UN reclassification by seventeen years. The US government knew the Schedule IV medical value claim was false at least seventeen years before the UN formally acknowledged it. It held the patent that proved it knew.
A Mauritian citizen suffering from Parkinson's disease can be imprisoned under the Dangerous Drugs Act 2000 for cultivating a plant whose neuroprotective properties are covered by a patent owned by the government whose treaty the Mauritian state is enforcing. The absurdity is not incidental to the system. It is the system. The patent is public. The treaty is public. The Dangerous Drugs Act is public. The citizen's Parkinson's disease is real. The contradiction is complete.
The patent itself: US Patent 6,630,507, "Cannabinoids as antioxidants and neuroprotectants." United States Patent and Trademark Office. Granted 7 October 2003. Publicly searchable at: patents.google.com/patent/US6630507. No registration required. The full text, including the abstract, claims, inventors, and assignee, is freely accessible to any reader on earth.
The assignee: The United States of America as represented by the Department of Health and Human Services. This is verifiable directly from the patent record. The Department of Health and Human Services is the federal department responsible for public health in the United States, the parent body of the National Institutes of Health where the research was conducted.
Julius Axelrod: Nobel Laureate in Physiology or Medicine, 1970, shared with Ulf von Euler and Bernard Katz for work on neurotransmitters. His Nobel Prize biography is publicly available at nobelprize.org. His role as a co-inventor on Patent 6,630,507 is confirmed in the patent record.
DEA Schedule I classification of cannabis: US Drug Enforcement Administration, Schedules of Controlled Substances. Cannabis (marijuana) has been maintained in Schedule I, defined as having no currently accepted medical use, since the Controlled Substances Act of 1970. The current Schedule I listing is publicly available at dea.gov. The simultaneous existence of Patent 6,630,507 and the Schedule I classification is a matter of verifiable public record requiring no secondary source.
Academic analysis of the contradiction: Aggarwal SK, "Cannabinergic Pain Medicine: A Concise Clinical Primer and Survey of Randomized-Controlled Trial Results." Clinical Journal of Pain, 2013. Boire R, Feeney K, "Medical Marijuana Law," Ronin Publishing, 2006. The contradiction between Patent 6,630,507 and Schedule I has been noted in academic drug policy literature since the patent was granted.
This is the fifteenth article in The Colonised Plant: The Cannabis Edition, June 2026, and the fifth in Chapter Three: The Criminalisation. The next article in Chapter Three turns from the international architecture of prohibition to the Mauritian soil in which that architecture is rooted: Grave 23 at Le Morne Old Cemetery, and what the bones of the ancestors reveal about the medicine we criminalised. The complete edition is published at themeridian.info/june-2026.
Add comment
Comments